IGC Pharma, Inc. (IGC) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of a loss of $0.02. This compares to a loss of $0.04 per share a year ago.
IGC Pharma, Inc. (IGC) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to loss of $0.09 per share a year ago.
IGC Pharma, Inc. (IGC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
14 Aug 2025 (In 2 weeks) Date | | - Cons. EPS | - EPS |
5 Aug 2025 (In 1 week) Date | | - Cons. EPS | - EPS |
30 Jun 2025 Date | | - Cons. EPS | - EPS |
24 Jun 2025 Date | | - Cons. EPS | - EPS |
18 Jun 2025 Date | | - Cons. EPS | - EPS |
14 Aug 2025 (In 2 weeks) Date | | - Cons. EPS | - EPS |
5 Aug 2025 (In 1 week) Date | | - Cons. EPS | - EPS |
30 Jun 2025 Date | | - Cons. EPS | - EPS |
24 Jun 2025 Date | | - Cons. EPS | - EPS |
18 Jun 2025 Date | | - Cons. EPS | - EPS |
Conglomerates Industry | Industrials Sector | Ram Mukunda CEO | XSTU Exchange | US45408X3089 ISIN |
US Country | 67 Employees | - Last Dividend | 19 Apr 2013 Last Split | 13 Apr 2006 IPO Date |
IGC Pharma, Inc., initially known as India Globalization Capital, Inc., is a transformative clinical stage biotechnology firm that has carved out a niche in developing innovative cannabinoid-based treatments. With its rebranding in March 2023, IGC Pharma has sharpened its focus on addressing a variety of diseases and conditions that significantly impact human health, such as Alzheimer's disease, dysmenorrhea, premenstrual syndrome (PMS), and chronic pain. Founded in 2005 and based in Potomac, Maryland, the company leverages cutting-edge science to pioneer treatments aimed at improving the quality of life for patients across these challenging conditions.
IGC Pharma, Inc. is at the forefront of research and development in the realm of cannabinoid-based therapeutics, with a robust pipeline that includes investigational drug assets and wellness brands.
This investigational drug is currently in a Phase 2B clinical trial and is designed as a potential treatment for agitation in dementia due to Alzheimer's disease. IGC-AD1 represents IGC Pharma’s commitment to addressing the complexities of Alzheimer’s, focusing on one of its most distressing manifestations.
Still in the pre-clinical development stage, TGR-63 is another promising investigational asset targeting Alzheimer's disease. This drug is part of IGC Pharma's strategic efforts to diversify its portfolio in the fight against neurodegenerative diseases, showcasing the company's dedication to groundbreaking research.
A wellness brand marketed by IGC Pharma, Holief targets women experiencing PMS and menstrual cramps. Emphasizing natural, cannabinoid-based relief, Holief stands as a testament to the company’s initiative to not only focus on clinical therapeutics but also offer wellness products that aid in everyday discomforts associated with menstrual health.